Although challenges associated with pharmacogenetic and genomic testing include the cost of testing, interpretation of genetic data, and integration of pharmacogenomics into clinical decisions, the potential of pharmacogenomics to optimize decision making remains an evolving field with growing importance in HER2+ BC management. Here, ERBB2 is linked to breast cancer.